Antisense and RNAi Therapeutics Market (By Technology: RNA Interference, Antisense RNA; By Application: Ocular, Genetic; By Route of Administration: Intrathecal, Intravenous) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global antisense and RNAi therapeutics market size was estimated at around USD 4.41 billion in 2023 and it is projected to hit around USD 24.59 billion by 2033, growing at a CAGR of 18.75% from 2024 to 2033. The antisense and RNAi therapeutics market is driven by the expanded therapeutic applications, demand for targeted therapies, and technological advancements.

Key Pointers

• North America dominated the market with the largest market share of 65% in 2023.
• Europe antisense and RNAi therapeutics market is forecasted to witness substantial growth.
• By Technology, the antisense RNA segment held the largest market share in 2023.
• By Technology, the RNA interference technology segment is expected to expand at the highest CAGR of 19.56% from 2024 to 2033.
• By Application, the neurodegenerative disorders segment generated the maximum market share of 68% in 2023.
• By Application, the genetic disorders segment is anticipated to grow at the noteworthy CAGR of 19.66% between 2024 to 2033.
• By Route of Administration, the intrathecal injections segment registered the maximum market share of 44% in 2023.
• By Route of Administration, the subcutaneous injection segment is poised to witness the highest compound annual growth rate (CAGR) of 19.98% from 2024 to 2033.

Antisense and RNAi Therapeutics Market Overview

Antisense and RNAi therapeutics function by targeting specific RNA molecules involved in disease processes. Antisense technology involves the use of synthetic nucleic acid sequences to bind complementary RNA sequences, thereby modulating gene expression. RNA interference, on the other hand, utilizes small RNA molecules to silence gene expression by degrading target RNA molecules.

Antisense and RNAi Therapeutics Market Growth

The growth of the antisense and RNAi therapeutics market is fueled by several key factors. Firstly, advancements in nucleic acid technologies have led to the development of more efficient and precise therapeutic agents, driving the expansion of the market. Additionally, increasing research and development activities in the field have uncovered new therapeutic targets and expanded the therapeutic applications of antisense and RNAi technologies. Furthermore, the rising demand for targeted therapies with fewer side effects has spurred the adoption of antisense and RNAi therapeutics across various disease areas, including oncology, infectious diseases, genetic disorders, and neurological disorders. Moreover, strategic collaborations between pharmaceutical companies and research institutions have accelerated the development and commercialization of novel therapeutics, further propelling market growth. Lastly, favorable regulatory frameworks and streamlined approval processes have facilitated the entry of new antisense and RNAi therapeutics into the market, driving innovation and investment in the sector. Overall, these growth factors collectively contribute to the expansion and advancement of the antisense and RNAi therapeutics market.

Antisense and RNAi Therapeutics Market Dynamics

Drivers

• Expanded Therapeutic Applications: Increasing research and development efforts have led to the identification of new therapeutic targets and expanded the applications of antisense and RNAi technologies across various disease areas.
• Demand for Targeted Therapies: Growing preference for targeted therapies with fewer side effects has fueled the adoption of antisense and RNAi therapeutics, particularly in oncology, infectious diseases, genetic disorders, and neurological disorders.

Restraints

• Immunogenicity Concerns: The use of nucleic acid-based therapeutics can elicit immune responses in some patients, leading to potential adverse effects and reduced efficacy. Addressing immunogenicity concerns is crucial for ensuring the safety and efficacy of antisense and RNAi therapeutics in clinical settings.
• Off-Target Effects: Non-specific binding of antisense and RNAi molecules to unintended RNA sequences can result in off-target effects, potentially causing unintended biological effects or adverse reactions. Minimizing off-target effects while maximizing target specificity remains a key challenge in the development of these therapies.

Opportunities

• Personalized Medicine: Antisense and RNAi therapeutics offer the potential for personalized treatment approaches tailored to individual patients based on their genetic makeup and disease characteristics. Advancements in genomics and molecular diagnostics provide opportunities for identifying specific molecular targets and designing customized therapeutic interventions, thereby optimizing treatment outcomes and minimizing adverse effects.
• Combination Therapies: The versatility of antisense and RNAi technologies allows for the development of combination therapies targeting multiple disease pathways or molecular targets simultaneously. By combining complementary therapeutic modalities, such as small molecules, monoclonal antibodies, or immune checkpoint inhibitors, synergistic effects can be achieved,

Technology Insights

In 2023, the antisense RNA segment held the largest market share, primarily due to its dominance in revenue generation. Antisense RNA molecules are extensively studied for their potential in controlling various conditions by regulating protein and gene expression. The broad applicability of this technology across cardiovascular, respiratory, neurodegenerative, and genetic disorders is expected to drive segment growth. Numerous studies are underway to evaluate antisense therapeutics for a wide range of disorders. For example, a study published by MDPI in August 2023 concluded that antisense oligonucleotide (ASO) therapies show significant promise in treating various disorders, including infectious diseases. Positive findings from such studies are anticipated to bolster demand for antisense RNA technology in the coming years.

Conversely, the RNA interference technology segment is projected to witness a higher compound annual growth rate (CAGR) of 19.56% over the forecast period. This technique is utilized to investigate gene functions in model organisms and cell cultures and target specific gene sequences implicated in cancer. Additionally, RNAi technology finds extensive applications in treating bacterial diseases, viruses, parasites, and alleviating pain.

Application Insights

In 2023, the neurodegenerative disorders segment commanded the largest market revenue share, accounting for 68%. Industry participants are actively pursuing advancements in RNAi and antisense therapies to address neurodegenerative diseases. For instance, in June 2023, Arrowhead Pharmaceuticals announced its intention to seek regulatory approval in Australia to commence a study on an investigational RNA interference-based therapy for amyotrophic lateral sclerosis (ALS), a neurological disorder. Such initiatives from major companies targeting neurodegenerative conditions are anticipated to fuel segment growth.

On the other hand, the genetic disorders segment is forecasted to exhibit the highest compound annual growth rate (CAGR) of 19.66% over the forecast period. The field of oligonucleotide medicines is rapidly expanding, evident from the increasing number of research studies. Companies are adopting diverse approaches to develop antisense and RNAi therapeutics for genetic diseases. For example, in June 2023, Charles River Laboratories International, Inc. collaborated with the Korean biotechnology company, Curigin, to produce oncolytic RNA interference (RNAi) gene therapy

Route Of Administration Insights

In 2023, the intrathecal injections segment emerged as the market leader, capturing a share of 44%. This method involves administering drugs via injection into the subarachnoid space or spinal canal to reach the cerebrospinal fluid. Intrathecal injections are commonly used in spinal anesthesia, chemotherapy, pain management, and delivering drugs to combat specific infections, particularly post-neurosurgical procedures. The route of drug administration plays a critical role in the effectiveness of every genetically modified molecule.

Conversely, the subcutaneous injection segment is poised to witness the highest compound annual growth rate (CAGR) of 19.98% over the forecast period. Subcutaneous injections are administered into the fatty tissue just beneath the skin. This method offers flexibility in selecting the infusion site, including options such as the abdomen, thighs, and back of the arms. Moreover, subcutaneous infusion systems can utilize smaller needle sizes, potentially reducing discomfort during the infusion process. These advantages associated with subcutaneous administration are expected to drive segment growth in the foreseeable future.

Regional Insights

In 2023, North America emerged as the dominant force in the global market, capturing a significant share of 65%. Moreover, the region is projected to experience the fastest compound annual growth rate (CAGR) during the forecast period. The United States, in particular, is witnessing the development of various RNAi therapies, with substantial investments from players in the biotechnology sector. Major pharmaceutical and biotechnology companies in North America are actively engaged in innovating RNAi therapeutics. For instance, in May 2023, Codexis, Inc., a U.S.-based organization, unveiled its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology platform for large-scale manufacturing of RNA oligonucleotide therapeutics. This innovative technology was introduced at the TIDES U.S. annual meeting, signaling significant advancements in the field. Such technological breakthroughs across the United States are poised to propel the North American market forward in the coming years.

Meanwhile, the Europe antisense and RNAi therapeutics market is forecasted to witness substantial growth. The region boasts the presence of various companies dedicated to antisense and RNAi therapeutics, driving regional expansion over the forecast period. These companies are actively pursuing initiatives to broaden their product portfolios and explore new business avenues. For instance, in March 2023, SciNeuro Pharmaceuticals, a U.S.-based organization, partnered with Europe-based Secarna Pharmaceuticals GmbH & Co. KG to develop novel antisense oligonucleotide (ASO) therapies targeting critical disease pathways in the Central Nervous System. This collaboration exemplifies the increasing focus of players from other regions on tapping into the European market potential, further fueling regional growth prospects in the foreseeable future.

Antisense And RNAi Therapeutics Market Key Companies

• GSK plc
• Olix Pharmaceuticals, Inc.
• Sanofi
• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma
• Benitec Biopharma Inc.
• Silence Therapeutics
• Ionis Pharmaceuticals, Inc
• Sarepta Therapeutics
• Percheron Therapeutics Limited

Antisense And RNAi Therapeutics Market Segmentations:

By Technology

• RNA Interference
• Antisense RNA

By Application

• Genetic Disease
• Cancer
• Infectious Disease
• Neurodegenerative Disorders
• Cardiometabolic & Renal Disorders
• Ocular Disorders
• Respiratory Disorders
• Skin Disorders

By Route of Administration

• Intravenous Injections
• Intrathecal Injections
• Subcutaneous Injections
• Other Delivery Methods

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA